Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive IDH-1 Mutant Glioma

NCT05484622 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT05484622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05484622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive IDH-1 Mutant Glioma
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 20, 2023
Completion date
August 30, 2027
Enrollment
60 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, oligodendroglioma